Clinical trial evaluating brain cancer vaccine is underway at NYUOctober 22, 2007A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center. The study will evaluate the addition of the vaccine following standard therapy with surgery and chemotherapy in patients with glioblastoma multiforme, a deadly form of brain cancer. The vaccine, called DCVax-Brain, incorporates proteins found in patients' tumors and is designed to attack cancer cells containing these proteins. The study underway at NYU Medical Center is an expansion of an earlier phase I trial of the vaccine. The vaccine is made by the Northwest Biotherapeutics, Inc., based in Bothell, Washington. "We are really excited about the promise of this vaccine," said Patrick J. Kelly, M.D., the chairman of the Department of Neurosurgery and the Joseph Ransohoff Professor of Neurosurgery at NYU School of Medicine. "Everything now depends on something in addition to surgery so that these tumors do not recur. A cancer vaccine like this may make a difference in extending life and maintaining a good quality of life."
"This is a form of individualized therapy," adds NYU neuro-oncologist Michael Gruber, M.D. "There is a lot of promise with this approach," he says. He and Dr. Kelly will be the lead investigators conducting the trial at NYU. Despite surgery and chemotherapy, patients with glioblastoma multiforme brain cancer typically survive about 15 months. Even if only a small number of tumor cells are left in the brain, that is enough for these fast growing and aggressive tumors to grow back. The tumors do not grow elsewhere in the body. "It is so frustrating," notes Dr. Kelly, "because brain tumors don't metastasize like other tumors. They recur locally but we just can't cure it." A brain cancer vaccine is intended as a kind of immunotherapy, which means that it primes the patient's own immune system to kill proteins found in cancer cells. The trial will enroll patients 18 to 65 years old with newly diagnosed glioblastoma multiforme brain cancer who will receive standard primary treatment with surgery followed by radiation with concurrent chemotherapy. Enrolled patients will be randomized to receive the standard of care, and others will receive the standard of care and the vaccine. The vaccine will be made from the tumors and immune cells of each patient. When a patient's tumor is removed during surgery it will be shipped to a laboratory where the tumor cells will be broken up to prepare the first component of the vaccine. Separately, patients' dendritic cells, a powerful type of immune cell, will be obtained and sent to a laboratory for purification. Dendritic cells may be able to teach the immune system to recognize and destroy cancer cells. The patients' tumor cell material is combined with the dendritic cells to form the vaccine. New York University Medical Center and School of Medicine Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Endangered Species Quasar Stress Allergic Reactions Groundwater Neurogenesis Cistic Fibrosis Transcription Influenza Virus Logging Nicotine Antiretroviral Therapy Polycystic kidney disease Biofilm Prions Cocaine Osteoarthritis Clinical Trials Volcanic Activity Hypertension Renewable energy Fishing Insulin Resistance Heterochromatin Vitamin
See More: Science News Tags | |||||||||||||||||||||
|
Related Brain Cancer Current Events and Brain Cancer News Articles UAB Researchers Draft 3-D Protein Map A new three-dimensional computer protein map is helping researchers at the University of Alabama at Birmingham (UAB) unravel the biological pathways that control brain-cell death after a stroke. Most common brain cancer may originate in neural stem cells University of Michigan scientists have found that a deficiency in a key tumor suppressor gene in the brain leads to the most common type of adult brain cancer. Cottonseed-Based Drug Shows Promise Treating Severe Brain Cancer, Say UAB Researchers An experimental drug derived from cottonseeds shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer. Tumor growth and chemo response may be predicted by mathematical model The aggressiveness of tumors and their susceptibility to chemotherapy may become easier to predict based on a mathematical model developed at The University of Texas Health Science Center at Houston. Moving gene therapy forward with mobile DNA Gene therapy is the introduction of genetic material into a patient's cells resulting in a cure or a therapeutic effect. In recent years, it has been shown that gene therapy is a promising technology to treat or even cure several fatal diseases for which there is no attractive alternative therapy. NASA's electronic nose may provide neurosurgeons with a new weapon against brain cancer An unlikely multidisciplinary scientific collaboration has discovered that an electronic nose developed for air quality monitoring on Space Shuttle Endeavour can also be used to detect odour differences in normal and cancerous brain cells. Novel cancer drug reduces neuroblastoma growth by 75 percent Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a new drug that restricts the growth of neuroblastoma, a childhood brain cancer. First noninvasive technique to accurately predict mutations in human brain tumors Donald O'Rourke, MD, Associate Professor of Neurosurgery at the University of Pennsylvania School of Medicine and colleagues, were able to accurately predict the specific genetic mutation that caused brain cancer in a group of patients studied using magnetic resonance imaging (MRI). TGen researchers discover possible way to block the spread of deadly brain tumors Researchers at the Translational Genomics Research Institute (TGen) may have found a way to stop the often-rapid spread of deadly brain tumors. Brain metastases hijack neuron-supporting cells to resist chemotherapy Cancer that spreads to other organs finds a particularly inviting hideout in the brain, where these metastases are usually far harder to treat than they are in other locations. More Brain Cancer Current Events and Brain Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||